BridgeBio PharmaBBIO.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, BridgeBio Pharma (BBIO.O) trades at a negative P/E (-18.76x, due to a recent net loss), P/B of Negative, P/S of 18.20x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/S sits at the 13th percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: P/B percentile data for BridgeBio Pharma is still accumulating, both within its industry and across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.48%, ranking at the 71st percentile over the trailing 20Y window.
Shareholder returns here lean heavily on buybacks rather than cash dividends. BridgeBio Pharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: BBIO · BBIO
Want the full picture on whether BridgeBio Pharma (BBIO.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -18.76 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | -5.16 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/S (TTM) | 18.20 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.48% |